Lyka Labs inks out-licensing deal with US-based generics firm

Lyka Labs Ltd, a pharmaceutical company that focuses on super specialty segments of injections and dermatology, has entered into an out-licensing & technology transfer deal with an US-based generics company for a basket of 12 sterile injectable formulations for manufacturing, sales and distribution in the US. Lyka has neither disclosed the name of the partnering company nor the financial details of the deal.

The market size of the licensed formulations is approximately $ 1.4 billion as per IMS March 2017. Lyka will be eligible for a royalty on end sales.

“Going forward, Lyka will continue to explore opportunities to monetise its R&D